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More candidates with creatinine levels  2 mg/dL have undergone liver transplantation (LT) since the implementation of Model
for End-Stage Liver Disease (MELD)–based allocation. These candidates have higher posttransplant mortality. This study
examined the effect of serum creatinine on survival benefit among candidates undergoing LT. Scientific Registry of Transplant
Recipients data were analyzed for adult LT candidates listed between September 2001 and December 2006 (n  38,899). The
effect of serum creatinine on survival benefit (contrast between waitlist and post-LT mortality rates) was assessed by sequential
stratification, an extension of Cox regression. At the same MELD score, serum creatinine was inversely associated with
survival benefit within certain defined MELD categories. The survival benefit significantly decreased as creatinine increased for
candidates with MELD scores of 15 to 17 or 24 to 40 at LT (MELD scores of 15-17, P  0.0001; MELD scores of 24-40, P 
0.04). Renal replacement therapy at LT was also associated with significantly decreased LT benefit for patients with MELD
scores of 21 to 23 (P  0.04) or 24 to 26 (P  0.01). In conclusion, serum creatinine at LT significantly affects survival benefit
for patients with MELD scores of 15 to 17 or 24 to 40. Given the same MELD score, patients with higher creatinine levels
receive less benefit on average, and the relative ranking of a large number of wait-listed candidates with MELD scores of 15
to 17 or 24 to 40 would be markedly affected if these findings were incorporated into the allocation policy. Liver Transpl 15:
1808-1813, 2009. © 2009 AASLD.
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Liver transplantation (LT) has altered the natural his-
tory of end-stage liver disease and is now considered
the preferred therapy for a wide range of previously
fatal chronic liver diseases. Optimal timing of LT in
the course of disease is desirable to avoid harm from
intervening too early and futility from transplanting
too late.
Serum creatinine is one of the key components of the
Model for End-Stage Liver Disease (MELD) score.1 The
proportion of candidates undergoing LT with serum
creatinine levels  2 mg/dL has increased by 25% dur-
ing the MELD era.2 Similarly, the proportion of candi-
dates receiving renal replacement therapy at the time of
LT has also increased by 43%.2 These candidates have
poorer patient and graft survival in comparison with
those who have serum creatinine levels  2 mg/dL at
the time of LT.2 Therefore, the use of MELD as the basis
of liver allocation may be shifting mortality from the
Abbreviations: HR, hazard ratio; INR, international normalized ratio; LT, liver transplantation; MELD, Model for End-Stage Liver
Disease; SD, standard deviation.
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waitlist to the posttransplant period by favoring LT for
candidates with more severe renal disease.
Previous analyses of United States national data have
found that the survival benefit of LT increases with
increasing MELD scores.3,4 In contrast to post-LT mor-
tality, waitlist mortality strongly depends on the MELD
score. Candidates with a low MELD score face a rela-
tively low waitlist mortality risk and do not benefit from
LT as much as those with high MELD scores. Merion et
al.4 found that candidates with MELD scores less than
15 experienced significantly greater mortality post-
transplant than they did on the waitlist, and this im-
plies that such candidates are better served by remain-
ing on the waitlist.
A recent analysis of data from the Scientific Registry
of Transplant Recipients demonstrated that serum cre-
atinine is overweighted in the existing MELD formula.5
Specifically, given two candidates with the same MELD
score, the one with a higher serum creatinine level has
a significantly lower mortality risk than the other with a
lower serum creatinine level (P  0.001).5 Because
MELD is an additive function of its three components
(creatinine, bilirubin, and the international normalized
ratio), these candidates must have reciprocal differ-
ences in the other two components; that is, candidates
with higher serum creatinine levels must have lower
bilirubin levels and/or international normalized ratios
in comparison with their counterparts with lower se-
rum creatinine levels and the same MELD score.
Serum creatinine is one of the strongest predictors of
waitlist1,6 and post-LT survival,2,7-9 being inversely as-
sociated with both endpoints. In light of the results we
have described in the preceding paragraphs, it is natu-
ral to ask whether candidates with equal MELD scores
(but different creatinine levels) derive equal survival
benefit from LT. To date, the evaluations of LT benefit
have assumed that candidates with equal MELD scores
benefit equally from LT, regardless of differences in
their MELD components.3,4 The aim of this study was
to assess the effects of differences in pretransplant se-
rum creatinine in a contemporary cohort of LT waitlist
candidates with the same MELD scores on the survival
benefit of LT using national data from the Scientific
Registry of Transplant Recipients database.
PATIENTS AND METHODS
Data Source and Study Population
This study used data from the Scientific Registry of
Transplant Recipients for all wait-listed adult candi-
dates in the United States submitted by the members of
the Organ Procurement and Transplantation Network,
and it was supplemented by mortality information from
the Social Security Death Master File.
The study population included candidates 18 years of
age or older with an initial date of registration for de-
ceased donor LT between September 1, 2001 and De-
cember 31, 2006. The start date of the study corre-
sponded to the initial date of mandatory submission of
the three components of the MELD score. Patients were
followed to death, receipt of a living donor transplant,
loss to follow-up, or the end of the observation period on
December 31, 2006, whichever occurred first. Candi-
dates listed as status 1, listed for repeat LT, or listed
with an exception MELD score were excluded.
Statistical Analysis
The analysis was based on sequential stratification,10
an extension of Cox regression for evaluating time-de-
pendent treatments, such as transplantation, in the
presence of time-dependent patient characteristics,
such as the MELD score or MELD score components. A
separate stratum has been created for each deceased
donor LT. Each stratum included the transplant recip-
ient as well as a set of matched candidates; specifically,
these were candidates who were active on the waitlist,
had the same MELD score, came from the same organ
procurement organization donation service area, and
had spent the same previous time on the waitlist. For
each candidate in the stratum, the covariate vector was
defined on the basis of the candidate’s status at the
time of inclusion in the stratum. Once included in the
stratum, matched controls were censored only if they
underwent LT. The sequential stratification method, as
applied to the estimation of LT survival benefit, was
described in detail by Schaubel et al.11
Of note, we excluded candidates who were trans-
planted after being granted a MELD exception score.
Correspondingly, in setting up the matched sets (ie,
comparator waitlist candidates), we excluded candi-
dates if they already had been granted an exception
score at the time of the index candidate’s transplant.
However, if not, they were included and not censored if
later granted a MELD exception. The motivation for
handling exception score patients carefully is that the
MELD score for a patient granted an exception is arbi-
trary and therefore not comparable to an equal labora-
tory MELD score.
After each stratum was set up, all strata were com-
bined, and a stratified Cox model was fitted. The model
included MELD category–specific LT  creatinine prod-
uct terms in order to test the interaction between sur-
vival benefit and serum creatinine. An analogous ap-
proach was used for renal replacement therapy. The
model was adjusted for age, sex, race, diagnosis, creat-
inine, dialysis, albumin, sodium, body mass index, di-
abetes, portal vein thrombosis, hospitalization status,
education, primary insurance payer, comorbidities
such as angina, chronic obstructive pulmonary dis-
ease, cerebrovascular disease, and a history of previous
malignancy. Standard errors and P values were based
on a robust (sandwich) variance estimator that ac-
counted for the repetition of patients across strata.
As in many previous studies, the mortality hazard
ratio (HR) was used to measure the survival benefit of
LT.3,4 The HR can be interpreted as the post-LT mor-
tality risk divided by the waitlist mortality risk, with all
other covariates being equal. If HR is greater than one,
then post-LT mortality is greater than mortality on the
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waitlist, and this implies that no LT survival benefit is
received. Conversely, if HR is less than one, then
post-LT mortality is lower with respect to mortality on
the waitlist, and this means that a survival benefit ex-
ists. When HR equals one, post-LT mortality and wait-
list mortality are equal. The models allowed the post-
LT/waitlist HR to differ by MELD score, serum
creatinine, and receipt of renal replacement therapy.
Furthermore, the degree to which creatinine and renal
replacement therapy each affected LT benefit was al-
lowed to differ by MELD category. To estimate the in-
teraction between survival benefit and serum creati-
nine, we began with the MELD categories used in
several previous analyses.3,4 In the interests of parsi-
mony and to increase precision, adjacent categories
with similar interaction estimates were then combined.
All statistical analyses were conducted with SAS ver-
sion 9.1.3 (SAS Institute, Cary, NC).
RESULTS
Cohort Characteristics at the Time of Listing
and Transplantation
Among the candidates (n  38,899) in the cohort ana-
lyzed, 15,318 underwent transplantation (deceased do-
nor LT, n  14,367, and living donor LT, n  951),
12,904 were removed from the list (died, n  6490;
exceptions, n  4697; and removed for other reasons,
n  1717), and 10,677 candidates were still on the
waitlist (active status, n  9136, and inactive status,
n  1541) at the end of the study period.
Table 1 shows the baseline characteristics of the LT
candidates at the time of listing. The median candidate
age was 53 years, 65% were male, 73% were white, and
74% had noncholestatic liver disease. The median
MELD score at listing was 14. Figure 1 shows the pro-
portions of candidates with serum creatinine levels of
1, 1.0 to 1.5, or 1.5 mg/dL and on renal replacement
therapy in different MELD categories at LT. The propor-
tion with serum creatinine levels  1.5 mg/dL was
higher among candidates with higher MELD scores (9-
11, 2%; 12-14, 7%; 15-17, 15%; 18-20, 23%; 21-23,
31%; 24-26, 39%; 27-29, 44%; 30-39, 56%; and 40,
44%). Similarly, the proportion of candidates on renal
replacement therapy was higher among candidates
with high MELD scores (18-20, 1.3%; 21-23, 6%; 24-
26, 6.5%; 27-29, 10%; 30-39, 21%; and 40, 48%).
Survival Benefit by Serum Creatinine by
MELD Category
With the same MELD score, a higher serum creatinine
level at LT was associated with less survival benefit.
This inverse effect of serum creatinine was significant
at MELD scores of 15 to 17 (P  0.0001) and 24 to 40
(P  0.04). The interaction between survival benefit and
serum creatinine was found to be quite similar for the
MELD categories of 24 to 26, 27 to 29, 30 to 39, and 40;
therefore, these categories were combined. Despite
these observations, the majority of candidates with
MELD scores of 15 to 17 and serum creatinine levels 
2.5 mg/dL (99.5%) and all candidates with MELD
scores of 24 to 40 at the time of LT had survival benefit.
However, the magnitude of the survival benefit for can-
didates with high creatinine levels was lower than that
of their counterparts with the same MELD scores but
lower serum creatinine levels (Fig. 2A,B).
































MELD score 16.3 (14)  7.7
Creatinine (mg/dL) 1.27 (1.0)  1.15
Bilirubin (mg/dL) 4.67 (2.3)  7.21
INR 1.54 (1.4)  0.70
Abbreviations: INR, international normalized ratio;
MELD, Model for End-Stage Liver Disease; SD, standard
deviation.
Fig 1. Distribution of serum creatinine and renal replace-
ment therapy at liver transplantation within each MELD cat-
egory. Abbreviations: Cr, creatinine; MELD, Model for End-
Stage Liver Disease.
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For patients with MELD scores of 12 to 14 or 18 to 23,
differences in serum creatinine at LT did not affect the
survival benefit (P  0.12 and P  0.69). Nearly 93% of
candidates with serum creatinine levels  1.3 mg/dL in
the MELD category of 12 to 14 and 100% of candidates
in the MELD category of 18 to 23 derived survival ben-
efit from LT.
Survival Benefit by Renal Replacement
Therapy by MELD Category
Figure 3 shows the effect of serum creatinine and
renal replacement therapy on survival benefit for
MELD categories of 21 to 23 and higher. Although
candidates derived survival benefit from LT, those
who were on renal replacement therapy had signifi-
cantly less survival benefit than those who were not
for MELD scores of 21 to 23 (P  0.04) and for MELD
scores of 24 to 26 (P  0.01). Mathematically, the
minimum MELD score for a candidate who is on renal
replacement therapy is 20. Therefore, the effect of
renal replacement therapy was not evaluated for
lower MELD categories.
Variation in Survival Benefit by MELD
Category
Figure 4 presents the covariate-adjusted distribution of
the HR of survival benefit attributable to renal replace-
ment therapy and serum creatinine at the time of LT
within each MELD category. Based on serum creatinine
or renal replacement therapy at the time of LT, the
survival benefit varied extensively within each MELD
category. For example, among those with MELD scores
of 15 to 17, from the lowest to highest creatinine levels,
the mortality risk post LT (versus wait-listed candi-
dates) was 70% to 26% lower.
Overall Survival Benefit by MELD Category
The overall covariate adjusted survival benefit (ratio of
post-LT mortality to waitlist mortality) in different
MELD categories is shown in Figure 5. Although this
Fig 2. (A) Survival benefit by creatinine: MELD scores of 15
to 17. The increasing trend in the hazard ratio (P < 0.0001)
as creatinine increases represents the interaction between
creatinine and survival benefit for MELD scores of 15 to 17.
There is no significant benefit of transplantation for creati-
nine > 2.5 mg/dL, which represents 0.5% of the patients in
this MELD category. (B) Survival benefit by serum creatinine:
MELD scores of 24 to 40. The increasing trend in the hazard
ratio represents the interaction between creatinine and sur-
vival benefit within each MELD category (P < 0.05 for each
category). Abbreviation: MELD, Model for End-Stage Liver
Disease.
Fig 3. Survival benefit by RRT and MELD. *P > 0.05 for
MELD scores of 27 to 29, 30 to 39, and 40. Abbreviations:
HR, hazard ratio; MELD, Model for End-Stage Liver Disease;
RRT, renal replacement therapy.
Fig 4. Distribution of the survival benefit based on serum
creatinine and renal replacement therapy at LT for different
MELD categories. The MELD categories include those for
which the survival benefit differs significantly by creatinine
(see Fig. 2). Within each category, survival benefit was esti-
mated for each transplanted patient using the MELD score,
creatinine, and dialysis status at transplant. Boxes contain
the middle 50% of the data, whereas whiskers represent min-
imums and maximums. Abbreviations: HR, hazard ratio; LT,
liver transplantation; MELD, Model for End-Stage Liver Dis-
ease.
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was not the main aim of this article, a survival benefit
was seen for all candidates with MELD scores  12.
There was no significant survival benefit for candidates
with MELD scores of 9 to 11 (HR  0.89, P  0.36).
Candidates with MELD scores of 6 to 8 had significant
harm associated with LT (HR  2.28, P  0.0001).
DISCUSSION
This is the first article to report the impact of individual
MELD components, namely, creatinine, on survival
benefit. The novel results of this study show that,
within certain MELD categories, higher serum creati-
nine and receipt of renal replacement therapy were as-
sociated with decreased LT survival benefit.
Our study was motivated in part by mathematical
properties inherent to the MELD score. Given that var-
ious sets of creatinine, bilirubin, and international nor-
malized ratio values produce the same score, MELD is
unable to discriminate between candidates with severe
synthetic dysfunction of the liver and well-preserved
renal function and those with serious renal disease in
the setting of well-preserved liver function. Thus, we
found that despite identical MELD scores, the relative
survival benefit from LT was different for candidates
with higher or lower serum creatinine levels at the time
of LT. In contrast, previous studies evaluating the sur-
vival benefit of LT implicitly assumed that candidates
with equal MELD scores benefited equally from LT, re-
gardless of differences in the individual MELD compo-
nents.3,4
The most important finding of this study is the in-
verse association between survival benefit and serum
creatinine for candidates with MELD scores of 15 to 17
or 24 to 40. Thus, although patients in the MELD cat-
egories of 15 to 17 and 24 to 40 had a survival benefit
from LT on average, our results indicated that individ-
ual candidates within these groups did not benefit
equally. These results have implications for current
candidate counseling, selection, and future organ allo-
cation policy development. If the ordering by survival
benefit for candidates with the same MELD scores were
factored into the current allocation system, it would
markedly affect the ranking of all patients on the wait-
list with MELD scores of 15 to 17 or 24 to 40.
Interaction between serum creatinine and survival
benefit was not observed in all MELD categories. As
shown in Figure 1, only a small proportion of patients in
the MELD categories with scores of 6 to 8, 9 to 11, and
12 to 14 had elevated creatinine, and the lack of vari-
ability in the creatinine values within these categories
made it unlikely that an interaction between survival
benefit and serum creatinine would be observed. Across
the remaining MELD score categories, the trend was
bimodal. The interaction was significant in the group
with MELD scores of 15 to 17, absent in the groups with
intermediate MELD scores of 18 to 20 or 21 to 23, and
significant again in the group with MELD scores  24.
Within a MELD category, as creatinine increases, bili-
rubin and/or the international normalized ratio neces-
sarily decrease. We speculate that in the middle range
(MELD scores of 18-20 and 21-23), there was an ap-
proximate balance between liver synthetic dysfunction
and renal dysfunction, such that no interaction was
observed between survival benefit and creatinine.
Candidates with MELD scores of 21 to 26 and who
were on renal replacement therapy at the time of LT
derived significantly less survival benefit in comparison
with those not receiving dialysis. Many studies have
shown that patients with renal insufficiency or on renal
replacement therapy at the time of LT have higher rates
of sepsis, more days spent in the intensive care unit,
and greater need for postoperative dialysis contributing
to posttransplant morbidity, mortality, and cost.7-9 Our
study indirectly adds support to such findings.
The lower survival benefit observed among patients
receiving renal replacement therapy was also not uni-
form across MELD scores (Fig. 3). For the interpretation
of this finding, it is important to refer back to Figure 1.
Specifically, serum creatinine levels among patients not
on renal replacement therapy increased markedly as
the MELD score increased. For example, patients not
on renal replacement therapy in the group with MELD
scores of 27 to 29 tended to have much higher serum
creatinine levels than those in the group with MELD
scores of 21 to 23. Therefore, the contrast between
patients on renal replacement therapy and those not on
renal replacement therapy with MELD scores of 21 to
23 was inherently much stronger than that in the
MELD category of 27 to 29. The adjustment for serum
creatinine had little effect in this case because of the
difficulty in interpreting high creatinine values for a
patient already on renal replacement therapy.
Pre-LT renal insufficiency has been reported to be an
important predictor of post-LT mortality,2,8 and within
this context, it is important to understand the relation-
ship between LT benefit and creatinine. The seminal
articles by Malinchoc et al.12 and Kamath et al.6 in the
development and validation of the MELD score ex-
cluded patients with intrinsic renal disease. In practice,
however, many candidates listed for LT have intrinsic
renal disease secondary to diabetes, hypertension, or
advanced age. Currently, there is no available mecha-
Fig 5. Covariate adjusted overall survival benefit by the
MELD score. The results are based on a maximum of 5 years of
posttransplant follow-up. *P > 0.05 for MELD scores of 9 to
11; P < 0.05 for all other MELD categories. Abbreviations:
HR, hazard ratio; MELD, Model for End-Stage Liver Disease.
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nism to account for patients with intrinsic renal disease
or rapidly changing renal function. MELD, per se, was
not intended to differentiate between intrinsic renal dis-
ease and hepatorenal syndrome.
Merion et al.4 did not show a significant overall survival
benefit of LT at MELD scores  18 on the basis of a data
set with a maximum of one year of posttransplant follow-
up. However, the authors predicted that, although the
ordering of HRs would remain the same across MELD
categories, survival benefit at all MELD scores would in-
crease with longer posttransplant follow-up. The present
study validated this overall prediction, demonstrating the
extension of significant survival benefit to candidates
transplanted with lower MELD scores (12-17) with up to
five years of post-LT follow-up.
The main limitation of the current study is related to
its retrospective observational design, which results in
the potential for bias due to unmeasured patient char-
acteristics and does not explicitly account for donor
factors. However, although LT is not randomly as-
signed, the degree to which patients are preferentially
selected for transplantation (ie, after consideration of
the extensive list of covariates for which adjustments
are made) is an open question. Creatinine, a key com-
ponent of the MELD score,1 is influenced by sex, age,
ethnicity, and muscle mass. Many patients with cirrho-
sis have muscle wasting, and serum creatinine may
overestimate renal function in such cases. The use of
serum creatinine in the calculation of the MELD score
has been criticized because of these limitations. Al-
though iothalamate clearance and 24-hour urine col-
lection for creatinine clearance are gold standards for
measuring glomerular filtration, serum creatinine is
still the most widely used and accepted measure of
renal function in patients with liver disease.
In conclusion, serum creatinine at the time of LT is an
important predictor of LT survival benefit independent
of the MELD score within certain MELD categories. The
ordering of many candidates in these MELD categories,
even among those with the same MELD score, would
change if the calculated survival benefit were a major
criterion for deceased donor organ allocation. The re-
sults of this study support the continued evolution of
the current urgency-based liver allocation toward one
based on survival benefit.
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